Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2026)
Zenas BioPharma's (ZBIO) quarterly Income from Continuing Operations came in at 80987000.0 in Q1 2026, down 141.23% year-on-year from 196443649.38 in Q1 2025, and up 67.75% quarter-over-quarter from 251135000.0 in Q4 2025.
Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Zenas BioPharma's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 80987000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 141.23% year-over-year to 80987000.0 in Q1 2026; TTM through Mar 2026 was 435844000.0, a 168.49% decrease from a year earlier, with the FY2025 full-year figure at 388430000.0, down 147.43% from the prior year.
- Income from Continuing Operations rose to 80987000.0 in Q1 2026 per ZBIO's latest filing, from 251135000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 35624000.0 in Q3 2023 and bottomed at 251135000.0 in Q4 2025.
- The 4-year median for Income from Continuing Operations is 38606000.0 (2024), against an average of 56655818.18.
- Biggest YoY gain for Income from Continuing Operations was 20.77% in 2025; the steepest drop was 381.33% in 2025.
- Year by year, Income from Continuing Operations stood at 32863000.0 in 2023, then slumped by 58.77% to 52175000.0 in 2024, then tumbled by 381.33% to 251135000.0 in 2025, then soared by 67.75% to 80987000.0 in 2026.
- Per Business Quant, the three latest ZBIO Income from Continuing Operations figures stand at 80987000.0 (Q1 2026), 251135000.0 (Q4 2025), and 51499000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Zenas BioPharma | 1.72 Bn | 1.72 Bn | - | -80.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.99 Mn |
| Dec 31, 2025 | -251.14 Mn |
| Sep 30, 2025 | -51.50 Mn |
| Jun 30, 2025 | -52.22 Mn |
| Mar 31, 2025 | -33.57 Mn |
| Dec 31, 2024 | -52.18 Mn |
| Sep 30, 2024 | -38.61 Mn |
| Jun 30, 2024 | -37.98 Mn |
| Mar 31, 2024 | -27.80 Mn |
| Dec 31, 2023 | -32.86 Mn |
| Sep 30, 2023 | 35.62 Mn |